|
Accurate
prediction of safety remains a major challenge in drug
development. Common
safety problems that arise include cardiotoxicity,
hepatotoxicity and nephrotoxicity. In
vitro
tests are routinely run in preclinical development in an attempt
to rapidly eliminate unsafe compounds and promote promising
potential candidates. Progress
has been made in developing higher-throughput techniques for the
early detection of compounds causing problems in the heart,
liver and kidney. When it comes to in
vivo screening one of the major challenges is accurately
predicting human drug toxicity with nonhuman animal models.
Preclinical
Drug Safety 2009
will evaluate the in
vitro &
in vivo toxicity screens in use today, assess how far
computational tools have come in helping to predict compound
toxicity and review imaging technologies used in safety
prediction. Some discussion will be included on idiosyncratic
and mitochondrial toxicity. A full session will be dedicated to
efforts being made to improve predictive
preclinical models
with special mention of species (e.g. rat-to-man) issues.
Attend
to learn more.
Topics to be Covered:
-
An Evaluation of In Vitro & In
Vivo Toxicity Screening
-
Hepatoxicity Assay Development
& Screening
-
Cardiovascular Safety Evaluation
-
Nephrotoxicity Assay Development
& Screening
-
Computational Tools for Predicting
Compound Toxicity
-
Imaging & Safety Screening
-
Mitochondrial Toxicity Testing in
Drug Development
-
Idiosyncratic Toxicity
-
Species Issues (e.g. Rat to Human)
-
Evidence-Based Toxicology
If you would like to submit a proposal
to give a presentation or display a poster at this meeting,
please submit a title and brief, 3-5 sentence summary of a
proposed topic on your recent work in the area of preclinical
drug safety.
All proposals are subject to review
by the Scientific Advisory Committee to ensure the highest
quality of the conference program.
Please click here to
submit your proposal.
The deadline for submission is August
15, 2008.
For questions or suggestions about
the meeting, please contact:
Edel O'Regan
Cambridge Healthtech Institute
250 First Avenue, Suite #300
Needham, MA 02494
Tel: 781-972-5423
Fax: 781-972-5425
email: eoregan@healthtech.com
For sales information, contact:
Carol Dinerstein
Tel: 781-972-5471
email: Dinerstein@healthtech.com
OR
Jon Stroup
Tel: 781-972-5483
email: jstroup@healthtech.com
|
